JP2016540977A5 - - Google Patents

Download PDF

Info

Publication number
JP2016540977A5
JP2016540977A5 JP2016532124A JP2016532124A JP2016540977A5 JP 2016540977 A5 JP2016540977 A5 JP 2016540977A5 JP 2016532124 A JP2016532124 A JP 2016532124A JP 2016532124 A JP2016532124 A JP 2016532124A JP 2016540977 A5 JP2016540977 A5 JP 2016540977A5
Authority
JP
Japan
Prior art keywords
mutant
mammal
beta
level
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016532124A
Other languages
English (en)
Japanese (ja)
Other versions
JP6592435B2 (ja
JP2016540977A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/066658 external-priority patent/WO2015077473A1/en
Publication of JP2016540977A publication Critical patent/JP2016540977A/ja
Publication of JP2016540977A5 publication Critical patent/JP2016540977A5/ja
Application granted granted Critical
Publication of JP6592435B2 publication Critical patent/JP6592435B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016532124A 2013-11-20 2014-11-20 アミロイド沈着を処置するための方法および組成物 Active JP6592435B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361906811P 2013-11-20 2013-11-20
US61/906,811 2013-11-20
PCT/US2014/066658 WO2015077473A1 (en) 2013-11-20 2014-11-20 Methods and compositions for treating amyloid deposits

Publications (3)

Publication Number Publication Date
JP2016540977A JP2016540977A (ja) 2016-12-28
JP2016540977A5 true JP2016540977A5 (https=) 2017-12-28
JP6592435B2 JP6592435B2 (ja) 2019-10-16

Family

ID=53180142

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016532124A Active JP6592435B2 (ja) 2013-11-20 2014-11-20 アミロイド沈着を処置するための方法および組成物

Country Status (10)

Country Link
US (1) US20170336395A1 (https=)
EP (1) EP3071240B1 (https=)
JP (1) JP6592435B2 (https=)
KR (1) KR20160079891A (https=)
AU (1) AU2014352944A1 (https=)
CA (1) CA2931220A1 (https=)
ES (1) ES2874704T3 (https=)
IL (1) IL245703B (https=)
MX (1) MX2016006584A (https=)
WO (1) WO2015077473A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7610923B2 (ja) * 2016-09-02 2025-01-09 スパーク セラピューティクス インコーポレイテッド Cns障害を治療するための方法及びベクター
CA3041548A1 (en) * 2016-11-04 2018-05-11 The Children's Hospital Of Philadelphia Gene transfer compositions, methods and uses for treating neurodegenerative diseases
JP7616995B2 (ja) * 2018-11-28 2025-01-17 プリベイル セラピューティクス,インコーポレーテッド 神経変性疾患のための遺伝子治療
WO2021026495A1 (en) * 2019-08-07 2021-02-11 Texas Tech University System Ad36e40rf1: a therapeutic treatment for alzheimer's disease
JP2023500793A (ja) * 2019-10-16 2023-01-11 コーネル・ユニバーシティー アルツハイマー病に対する遺伝子治療方法
EP4065600A1 (en) 2019-11-25 2022-10-05 Cornell University Apoe gene therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3002156A (en) * 1961-09-26 pumped solid state maser
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US6468524B1 (en) 2000-03-22 2002-10-22 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services AAV4 vector and uses thereof
US6855314B1 (en) 2000-03-22 2005-02-15 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector for transducing brain cells and lung cells
PT1416965E (pt) * 2001-08-17 2008-04-01 Lilly Co Eli Método de ensaio para a doença de alzheimer
WO2004108922A2 (en) * 2003-04-25 2004-12-16 The Trustees Of The University Of Pennsylvania Use of aav comprising a capsid protein from aav7 or aav8 for the delivery of genes encoding apoprotein a or e genes to the liver
WO2007022015A1 (en) * 2005-08-12 2007-02-22 Georgetown University Methods to evaluate amyloid beta-lowering agents using wild-type mice
EP1865326B1 (en) * 2006-06-08 2011-09-07 FU Berlin Assay for the diagnosis of Alzheimer's Disease based on the determination of the ratio of secretase Aß cleavage products
US20080234377A1 (en) * 2007-03-23 2008-09-25 Martek Biosciences Corporation Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
EP2575596B1 (en) * 2010-05-24 2016-04-20 The Washington University Methods of determining amyloid beta turnover in blood
WO2012135857A1 (en) * 2011-03-31 2012-10-04 University Of Iowa Research Foundation Methods and compositions for treating brain diseases
EP2511296A1 (en) * 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
KR20140072019A (ko) * 2011-07-13 2014-06-12 머크 샤프 앤드 돔 코포레이션 체액 샘플에서의 아밀로이드 베타 올리고머의 검출 방법 및 그의 용도

Similar Documents

Publication Publication Date Title
JP2016540977A5 (https=)
Tomono et al. Highly efficient ultracentrifugation-free chromatographic purification of recombinant AAV serotype 9
Powell et al. Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism
JP4559429B2 (ja) 空キャプシドを実質的に含まない組換えaavビリオン調製物を生成するための方法
Aslanidi et al. Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?
CN109121395B (zh) 腺相关病毒载体递送β-肌聚糖和微RNA-29以及肌营养不良症的治疗
JP2016503405A5 (https=)
CA2833908C (en) Cns targeting aav vectors and methods of use thereof
JP2021512072A5 (https=)
JP2019513393A5 (https=)
JP2016525347A5 (https=)
RU2018116076A (ru) Модифицированные гены атаксии фридрейха и векторы для генной терапии
JP2018148927A5 (https=)
IL292999A (en) Compositions and methods of treating amyotrophic lateral sclerosis (als)
JP2020096587A (ja) キャプシド
WO2016137949A4 (en) Regulatable expression using adeno-associated virus (aav)
JP2019511570A5 (https=)
RU2017125234A (ru) Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний
JP2018531609A5 (https=)
JP2020527333A5 (https=)
JP2019513779A5 (https=)
JP2017510298A5 (https=)
JP2018510648A5 (https=)
RU2016104614A (ru) Вектор aav и анализ на нейтрализующие антитела против aav (аденоассоциированного вируса)
EP2660325A3 (en) AAV vectors and corresponding nucleotide sequences and methods